Sabby Management’s Biolase, Inc. BIOL Stock Holding History

Sabby Management’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25	Closed	-$26K	–	196
2020 Q4	$26K	Sell	25 -108	-81%	-$82.4K	0.01%	105
2020 Q3	$92K	Buy	+133	New	+$125K	0.01%	119
2015 Q4	–	Sell	-23	Closed	-$255K	–	375
2015 Q3	$255K	Sell	23 -1	-4%	-$18.6K	0.01%	335
2015 Q2	$522K	Sell	24 -6	-20%	-$146K	0.02%	259
2015 Q1	$760K	Buy	+30	New	+$850K	0.03%	211

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM Advisors New York $220M AUM 23.37% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management's BIOL Position: Q1 2021 in Review

Sabby Management sold out of Biolase, Inc. (BIOL) in Q1 2021, closing a stake of 25 shares — an estimated $26K sold.

Sabby Management first reported a position in BIOL in Q1 2015 and held it in 5 quarters. The position peaked at $760K in Q1 2015. 32 funds tracked by Wall St. Rank hold BIOL as of Q1 2021.

Sabby Management reported no remaining Biolase, Inc. position as of Q1 2021 after selling out during the quarter.
Sabby Management sold 25 Biolase, Inc. shares in Q1 2021, an estimated $26K.
Sabby Management first reported a position in Biolase, Inc. in Q1 2015 and held it in 5 quarters.
Sabby Management's Biolase, Inc. position peaked at $760K in Q1 2015.
32 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.